Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

UGN-102 Showed Promising Long-Term Results in the Ph 3 ENVISION Trial

December 10, 2024

Long-Term Follow-up Study to the OLYMPUS Trial Reports Median Duration of Response of 4 Years in Patients Who Achieved a Complete Response with JELMYTO®

December 10, 2024

Positive Results Announced from Ph 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

December 10, 2024

FAILED TRIAL: Ph 3 KEYLYNK-001 Trial Met Primary Endpoint of PFS, but not OS, in Patients With Advanced Epithelial Ovarian Cancer

December 10, 2024

Positive Topline Results from Ph 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer Announced

December 4, 2024

FAILED TRIAL: Ph 3 SKYSCRAPER-01 study of tiragolumab + Tecentriq in patients with PD-L1-high 1L mNSCLC did not reach the primary endpoint of OS

December 4, 2024

Positive Initial Clinical Data Announced in Ph 1 Clinical Trial of SENTI-202 for the Treatment of R/R Hematologic Malignancies Including AML

December 4, 2024

Data from the FELIX study of obe-cel in R/R Adult B-ALL Patients published in NEJM

December 4, 2024

Continued Durable Remissions Reported in Ph 1 Trial of INB-200

December 4, 2024

New Data from the OLYMPUS Trial Show mDOR of Four Years in Patients Who Achieved a Complete Response with JELMYTO

December 4, 2024

Positive Final Results from Randomized Ph 2 Study of CM24 in 2L Pancreatic Cancer Reported

December 4, 2024

ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial Completed and CRR of 71% with a Durable DoR Ranging Up to 54 Months reported

November 26, 2024

Ph 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints

November 26, 2024

First Clinical Data on TCER® IMA402 Targeting PRAME announced

November 26, 2024

Truqap combination in PTEN-deficient mHSPC demonstrated statistically significant and clinically meaningful improvement in rPFS in CAPItello-281 Ph 3 trial

November 26, 2024

Eflornithine and Lomustine Combination Shows Clinically Meaningful Improvements in OS and PFS in Patients with Recurrent Astrocytoma IDH Mutant Grade 3

November 26, 2024

Favorable Preliminary PYX-201 Clinical Ph 1 Part 1 Data Announced

November 26, 2024

Encouraging updated interim Ph 2 data from GRANITE trial in 1L MSS-CRC announced

November 19, 2024

Blenrep shows OS improvement in DREAMM-7 Ph 3 trial for R/R multiple myeloma

November 19, 2024

FAILED TRIAL: Topline Data Announced from SELECT-MDS-1 Ph 3 Trial of Tamibarotene in Higher-Risk MDS with RARA Gene Overexpression

November 19, 2024

Lete-cel Achieves Primary Endpoint in Pivotal Trial

November 19, 2024

ECLIPSE Trial Meets Primary Endpoint, Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients With PSMA-Positive mCRPC

November 19, 2024

Annamycin + Ara-C achieved 60% CR/CRi in AML patients who were relapsed from or refractory to Venetoclax regimens

November 19, 2024

Efti Shows impressive Survival Data from INSIGHT-003 Trial in NSCLC

November 19, 2024

Ph 1 and iMMagine-1 studies of anito-cel in R/R multiple myeloma patients continue to demonstrate durability and a manageable safety profile

November 13, 2024
Page1 … Page5 Page6 Page7 Page8 Page9 … Page30

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.